Pregabalin Capsule
Product Images NDC 63629-8198

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8198). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298198)

Label for Pregabalin Capsules USP, 150 mg, manufactured by Bryant Ranch Prepack. The label includes the product NDC 63629-8198-01, dosage strength prominently displayed within a red border, and indicates a package size of 30 capsules. The Bryant Ranch Prepack logo appears near the bottom, with storage and safety instructions also visible.*

FDA Label Image

Label (Lbl6362981982)

Pregabalin 150 mg capsule label from Bryant Ranch Prepack. The label indicates the product is a white capsule and includes storage instructions to keep at room temperature (20°-25°C). The label compares to Lyrica 150 mg capsule and shows a package count of 30 capsules. The NDC number 63629-8198-1 is displayed, along with a barcode and a lot number.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph includes vertical reference lines at approximately 30% and 50% improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent improvement in pain from baseline to percent of patients improved. Two lines represent Pregabalin 100 mg three times a day and placebo. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows percent of patients improved from 0 to 100.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved relative to the percent improvement in pain from baseline. Four lines represent Pregabalin dosed at 300 mg, 150 mg, and 75 mg twice a day, and placebo. The graph demonstrates trends of patient improvement across increasing pain improvement percentages.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with the Pregabalin 200 mg group showing higher improvement percentages across most of the range.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows comparative efficacy trends of the two Pregabalin dosages against placebo across increasing pain improvement percentages.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

This figure presents bar charts from two clinical studies, Study E1 and Study E3, showing the responder rates (%) across different dosages and treatments compared to placebo. Study E1 includes placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day groups, while Study E3 compares placebo, 300 mg/day, and 600 mg/day in either BID or TID dosing. The chart highlights statistically significant increases in responder rates versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percentage change from baseline, plotted against dose in mg/day. Four studies are represented with different markers: Study E1 BD (solid circles), Study E2 TID (open squares), Study E3 BD (solid triangles), and Study E3 TID (open triangles). Significant p-values are noted for various dose comparisons, indicating seizure reduction at increasing doses compared to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 800 mg, 450 mg, and 300 mg daily doses compared to placebo. The graph shows four distinct lines, illustrating the efficacy of different Pregabalin doses and placebo on pain improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A survival curve chart comparing Pregabalin and placebo over 180 days, displaying the estimated percentage of subjects without LTR on the vertical axis and days on the horizontal axis. The graph uses solid and dashed lines to differentiate between Pregabalin and placebo groups.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line chart comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 BOCF for Pregabalin versus Placebo. The solid line represents Pregabalin, showing a higher percentage of improvement across the range compared to the dashed line representing Placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over a range of percentage improvements from baseline to week 16 BOCF. Two lines are shown: one solid line representing Pregabalin and one dashed line representing Placebo, illustrating the difference in percent improvement between these two groups.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

The image shows a formula for calculating creatinine clearance (CLcr). The formula uses age in years, weight in kilograms, and serum creatinine in mg/dL, with a correction factor of 0.85 applied for female patients. This text panel is likely part of clinical or pharmacokinetic information.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, depicting its molecular formula and stereochemistry as represented in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.